TUKYSA (tucatinib), along with trastuzumab and capecitabine, is a targeted oral treatment option. It’s for people with HER2+ metastatic breast cancer who have received at least 1 other treatment in the metastatic setting, such as trastuzumab, PERJETA® (pertuzumab), or KADCYLA® (trastuzumab emtansine).
TUKYSA is a prescription medicine used with the medicines trastuzumab and capecitabine to treat adults with human epidermal growth factor receptor-2 (HER2) positive breast cancer that has spread to other parts of the body such as the brain (metastatic), or that cannot be removed by surgery, and who have received one or more anti-HER2 breast cancer treatments.
TUKYSA* is Proven to Offer More Time
More time without the cancer growing and spreading
In the clinical study, the median amount of time without cancer progressing was 7.8 months with TUKYSA, along with trastuzumab and capecitabine, versus 5.6 months with trastuzumab and capecitabine alone.
Download for details: TUKYSA